Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
- PMID: 26351355
- DOI: 10.1200/JCO.2015.60.9347
Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
Abstract
Nasopharyngeal carcinoma of the undifferentiated subtype is endemic to southern China, and patient prognosis has improved significantly over the past three decades because of advances in disease management, diagnostic imaging, radiotherapy technology, and broader application of systemic therapy. Despite the excellent local control with modern radiotherapy, distant failure remains a key challenge. Advances in molecular technology have helped to decipher the molecular pathogenesis of nasopharyngeal carcinoma as well as its etiologic association with the Epstein-Barr virus. This in turn has led to the discovery of novel biomarkers and drug targets, rendering this cancer site a current focus for new drug development. This article reviews and appraises the key literature on the current management of nasopharyngeal carcinoma and future directions in clinical research.
© 2015 by American Society of Clinical Oncology.
Similar articles
-
Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma.Cancer Metastasis Rev. 2017 Sep;36(3):435-447. doi: 10.1007/s10555-017-9693-x. Cancer Metastasis Rev. 2017. PMID: 28819752 Free PMC article. Review.
-
Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.Hematol Oncol Clin North Am. 2008 Dec;22(6):1267-78, x. doi: 10.1016/j.hoc.2008.08.012. Hematol Oncol Clin North Am. 2008. PMID: 19010273 Review.
-
Review of nasopharyngeal carcinoma.Ear Nose Throat J. 2006 Mar;85(3):168-70, 172-3, 184. Ear Nose Throat J. 2006. PMID: 16615599 Review.
-
Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.Expert Rev Anticancer Ther. 2006 Mar;6(3):383-94. doi: 10.1586/14737140.6.3.383. Expert Rev Anticancer Ther. 2006. PMID: 16503855 Review.
-
Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.Cancer. 2003 Jul 15;98(2):288-91. doi: 10.1002/cncr.11496. Cancer. 2003. PMID: 12872347
Cited by
-
Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.Cancer Med. 2024 May;13(10):e7243. doi: 10.1002/cam4.7243. Cancer Med. 2024. PMID: 38752448 Free PMC article.
-
Prognostic value of sarcopenia in the patients with locally advanced nasopharyngeal carcinoma.Jpn J Radiol. 2024 May 10. doi: 10.1007/s11604-024-01587-3. Online ahead of print. Jpn J Radiol. 2024. PMID: 38727962
-
Specific-CT brain template construction and retrospective dosimetric comparison study in brain for nasopharyngeal carcinoma patients treated with IMRT or VMAT.Am J Cancer Res. 2024 Apr 15;14(4):1662-1674. doi: 10.62347/HACN9549. eCollection 2024. Am J Cancer Res. 2024. PMID: 38726278 Free PMC article.
-
Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.Cancer Control. 2024 Jan-Dec;31:10732748241251562. doi: 10.1177/10732748241251562. Cancer Control. 2024. PMID: 38716503 Free PMC article.
-
Differential analysis of histopathological and genetic markers of cancer aggressiveness, and survival difference in EBV-positive and EBV-negative prostate carcinoma.Sci Rep. 2024 May 5;14(1):10315. doi: 10.1038/s41598-024-60538-0. Sci Rep. 2024. PMID: 38705879 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous